Medtronic plc reported first quarter fiscal 2027 results ending July 31, 2026, with revenue of $9.8 billion, representing a 13.7% increase as reported and on an organic basis. GAAP diluted EPS was $1.14, while non-GAAP diluted EPS reached $1.45, both exceeding guidance. The company raised its full-year fiscal 2027 organic revenue growth guidance by 50 basis points to a range of 7.25% to 7.75% and increased the diluted non-GAAP EPS guidance to $5.94–$6.00. Cardiovascular portfolio revenue grew 18.9%, driven by strong performance in Cardiac Rhythm Management and Ablation Solutions, while Neuroscience and Medical Surgical segments also posted double-digit organic growth. Medtronic operates as a global leader in healthcare technology, developing medical devices and therapies for cardiovascular, neuroscience, diabetes, and surgical conditions.